Optimization of percutaneous coronary intervention using new stent designs and individualized antiplatelet therapy

Great improvement in the percutaneous treatment of obstructive coronary artery disease have been made over the past few decades. Recent developments have focused on alterations in stent design and the duration of dual antiplatelet therapy. The ReCre8 trial assessed clinical outcomes after implantation of the permanent polymer zotarolimus-eluting stent versus the polymer-free amphilimus-eluting stent, in both stable coronary artery disease and acute coronary syndromes. A special focus on patients with diabetes mellitus demonstrated a potential enhanced efficacy of a drug-eluting stent with an amphilimus formula, which appeared to be most pronounced in the first year following percutaneous coronary intervention. A short dual antiplatelet therapy duration of one month was assessed in patients with troponin-negative disease, demonstrating low rates of stent thrombosis after three years.